SI-BONE at Morgan Stanley conference: growth broadens beyond pelvis

SI-BONE reported 15% year-over-year Q2 revenue growth, a 19% increase in active physicians to roughly 720, adjusted EBITDA improvement of about 180%, and nearly $1 million of positive operating cash flow. New Medicare DRGs for Granite procedures, effective October 1, 2026, are expected to increase reimbursement by approximately $20,000 to more than $50,000 per procedure, with broader commercial adoption anticipated in 2027. Management also expects an alpha launch of its third FDA Breakthrough Device for spinal fusion and targets one to two new product launches annually, though medium-term gross margin is expected to normalize to 77%-78% from 79.5% as products scale.

Analysis

SIBN’s investable setup is a reimbursement-to-utilization story rather than a near-term pricing story. The October DRG implementation should first improve hospital willingness to stock and schedule cases; the larger revenue effect likely arrives over 1-3 quarters as hospital coding pathways and commercial-contract analogs catch up. The key incremental variable is implant units per case: if improved economics drives bilateral/two-point fixation, Granite revenue can outgrow procedure volume without requiring a proportional increase in new surgeons.

The more important 6-18 month upside is reduced physician churn and higher wallet share from a broader product bag. A hybrid direct/agent model can create meaningful sales-force productivity if new launches use existing spine call points, but management has not disclosed the new device’s addressable market, ASP, clearance status, or launch economics. Investors should not capitalize the “super-cycle” narrative until early alpha-launch reorder rates and surgeon conversion data establish that the product is more than a small adjacency.

Margin expectations imply a near-term accounting headwind from instrument and launch-related depreciation before volume absorbs capacity. That makes EBITDA execution and cash conversion more informative than gross margin over the next several quarters: sustained operating leverage despite a 150-250bp gross-margin normalization would validate the platform thesis. Conversely, a growth slowdown while launch spending rises would expose the risk that the current valuation already discounts a successful multi-product expansion.

Contrarian view: the market may be underestimating the lag between favorable reimbursement and realized demand, particularly in commercial channels, while overestimating the durability of temporary payment support for newer products. SIBN’s clean liquidity profile limits financing risk, but reimbursement implementation, FDA timing, and actual utilization—not balance-sheet capacity—are the gating risks.

Key Decisions for Investors

• Maintain a watch-to-buy stance on SIBN ahead of the next earnings report; initiate a long only if management demonstrates reacceleration in procedure/active-physician growth and confirms Granite unit-per-case expansion after DRG implementation. Target a 6-12 month position sized for 20-30% upside versus a 12-15% stop on evidence of adoption failure.
• For existing SIBN longs, use the October reimbursement effective date as an event marker rather than a profit-taking catalyst. Add only on post-implementation data showing hospital conversion and repeat use; a guidance cut, sub-15% growth without an explicit timing explanation, or gross margin below the stated medium-term range would falsify the operating-leverage thesis.
• Avoid treating the undisclosed spinal-fusion launch as underwritten 2027 revenue until FDA clearance, launch timing, ASP, and early reorder data are public. Establish alerts for clearance and the first quarterly disclosure of case volume or account adoption rather than purchasing upside options on management’s TAM claims.
• Consider a relative-value long SIBN / short XBI basket over 6-12 months only after the above utilization confirmation: SIBN’s idiosyncratic reimbursement and sales-productivity catalysts can decouple from biotech beta, while the pair limits broad risk-off exposure. Exit if CMS/payment implementation is delayed or early commercial adoption fails to follow Medicare uptake.